Allergy Therapeutics PLC Stock
€0.13
Your prediction
Allergy Therapeutics PLC Stock
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
Cons
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | 0.000% | 3.200% | 0.781% | 72.000% | 10.256% | 171.579% | -33.846% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | -28.302% | -20.833% | -12.037% | -15.179% | -25.490% | -63.462% |
| Eledon Pharmaceuticals Inc. | 2.870% | 2.286% | 29.710% | -60.222% | 39.844% | -34.672% | -85.748% |
| SELLAS Life Sciences Group Inc | 7.220% | -7.172% | -9.054% | 117.377% | 18.695% | 10.509% | -50.398% |
News
Why AT&T Stock Surged This Week
Shares of AT&T (NYSE: T) jumped more than 10% this past week, according to data from S&P Global Market Intelligence.
The wireless carrier delivered an impressive quarterly financial report and
Stock Market Today, Jan. 29: AT&T Climbs as Earnings Confirm Cash Flow Strength
AT&T (NYSE:T), a provider of wireless, broadband, and fixed-line telecom services, closed Thursday at $25.11, up 4.32%. The stock moved higher after analyst upgrades and a strong fourth-quarter 2025
AT&T's Lumen Deal Hides an Opportunity Most Investors Are Missing
Telecom giant AT&T (NYSE: T) agreed to pay $5.75 billion last year to acquire Lumen's fiber business. The deal, which is expected to close early this year, will add 4 million passed locations and 1


